Novartis | NOVN - Nettoeinkommen





Nettoeinkommen Veränderung Datum
AbbVie USD 695M 1.12B 2026-03
Alcon AG USD 189M 28M 2026-03
Almirall EUR 19.58M 7M 2025-12
Amgen USD 1.82B 486M 2026-03
AstraZeneca USD 3.08B 754M 2026-03
Autolus Therapeutics Ltd USD -90.33M 11.21M 2025-12
Bayer EUR 2.76B 6.52B 2026-03
Biogen USD 319.5M 368.4M 2026-03
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Eli Lilly USD 7.4B 760M 2026-03
Fresenius EUR 361M 17M 2025-12
Fresenius Medical Care EUR 118M 209M 2026-03
Genmab DKK 31M 370M 2025-12
Gilead Sciences USD 2.02B 162M 2026-03
GlaxoSmithKline GBP 1.74B 1.1B 2026-03
GRIFOLS EUR 73M 25.25M 2026-03
Hikma Pharmaceutical USD 164M 45M 2025-12
J&J USD 5.24B 119M 2026-03
Lakefront Biotherapeutics EUR 14.49M 767.65M 2026-03
Lonza CHF 426M 119M 2025-06
Merck EUR 659M 340M 2026-03
Merck USD -4.24B 7.2B 2026-03
Novartis USD 3.16B 747M 2026-03
Novartis USD 2.41B 1.52B 2025-12
Novo Nordisk DKK 26.89B 388M 2025-12
Orion EUR 90.4M 170.1M 2026-03
Pfizer USD 2.69B 4.34B 2026-03
Philips EUR 151M 244M 2026-03
Recordati EUR 153.06M 35.75M 2026-03
Regeneron Pharmaceuticals USD 727.2M 117.4M 2026-03
Roche Holding CHF 5.47B 1.76B 2025-12
Sanofi EUR 1.61B 2.42B 2026-03
UCB EUR 1.08B 608M 2025-12